Annual report
9158.TEDINET S100YKO7
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 147
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥54.4bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥47.0bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥33.0bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥35.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥35.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥5.8bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.1bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥2.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥97.9bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥85.2bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.8bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥39.8bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥34.5bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥63.9bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥54.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥34.0bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.3bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.0bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥33.4bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥29.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥27.3bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥11.7bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥9.5bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥15.8bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥8.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥4.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥5.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.2bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥3.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥4.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥14.7bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥6.7bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥14.4bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥4.0bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥97.35 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥93.99 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥97.35 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥106.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.99 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥113.9 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,139.32 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,012.38 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥931.79 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥533.1 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥453.12 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 34.1% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 34.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.5% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.4% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 9.0% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.3% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 22.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 38.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 5,740 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 5,145 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,743 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 2,994 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 2,470 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥7.4bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥7.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥14.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.6bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.4bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥949m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥65.8bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥56.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥45.5bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥28.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.4bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥32.6bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥24.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥23.5bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥22.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.9bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥32.38 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.63 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.01 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.21 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.53 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥822.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥797.1 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.3 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥365.69 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥335.57 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 29,990,400 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 29,990,400 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 29,990,400 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,152 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 416 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 467 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 434 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 423 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 374 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 63
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 3 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥148m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥148m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥27m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥475m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥475m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥933m |
| Hospicereportable segment | employees | at 2026-03-31 | 2335 pure |
| Hospicereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Hospicereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥16.7bn |
| Hospicereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥980m |
| In Home Nursingreportable segment | employees | at 2026-03-31 | 1647 pure |
| In Home Nursingreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥12.9bn |
| In Home Nursingreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥12.9bn |
| In Home Nursingreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥10m |
| In Home Nursingreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Medical Care Residencereportable segment | employees | at 2026-03-31 | 858 pure |
| Medical Care Residencereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| Medical Care Residencereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| Medical Care Residencereportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥262m |
| Medical Institutionreportable segment | employees | at 2026-03-31 | 739 pure |
| Medical Institutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥17.3bn |
| Medical Institutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥16.8bn |
| Medical Institutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥465m |
| Medical Institutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥54.7bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥54.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥475m |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥54.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥54.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥314m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥834m |
| Hospicereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Hospicereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| In Home Nursingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| In Home Nursingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Medical Care Residencereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Care Residencereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥299m |
| Medical Institutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥17.6bn |
| Medical Institutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥17.3bn |
| Medical Institutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Medical Institutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥46.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥47.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥314m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Medical Institutionreportable segment | employees | at 2026-03-31 | 258 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,860
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in trade and other payables ope cf IFRS | CurrentYearDuration | -659000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YearDuration | -96000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYearDuration | 52000000 | JPY |
| Increase decrease in accrued paid absences ope cf IFRS | Prior1YearDuration | 167000000 | JPY |
| Increase decrease in accrued paid absences ope cf IFRS | CurrentYearDuration | 169000000 | JPY |
| Decrease increase in other current assets ope cf IFRS | Prior1YearDuration | 20000000 | JPY |
| Decrease increase in other current assets ope cf IFRS | CurrentYearDuration | -397000000 | JPY |
| Increase decrease in other current liabilities ope cf IFRS | Prior1YearDuration | -347000000 | JPY |
| Increase decrease in other current liabilities ope cf IFRS | CurrentYearDuration | 303000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YearDuration | 618000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYearDuration | 227000000 | JPY |
| Subtotal ope cf IFRS | Prior1YearDuration | 5923000000 | JPY |
| Subtotal ope cf IFRS | CurrentYearDuration | 8400000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YearDuration | 24000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYearDuration | 88000000 | JPY |
| Interest paid ope cf IFRS | Prior1YearDuration | -550000000 | JPY |
| Interest paid ope cf IFRS | CurrentYearDuration | -654000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YearDuration | -2894000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYearDuration | -2128000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YearDuration | 2503000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYearDuration | 5706000000 | JPY |
| Purchase of financial assets measured at fair value inv cf IFRS | Prior1YearDuration | -520000000 | JPY |
| Purchase of financial assets measured at fair value inv cf IFRS | CurrentYearDuration | － | JPY |
| Proceeds from sale of financial assets measured at fair value inv cf IFRS | Prior1YearDuration | 411000000 | JPY |
| Proceeds from sale of financial assets measured at fair value inv cf IFRS | CurrentYearDuration | 0 | JPY |
| Purchase of property inv cf IFRS | Prior1YearDuration | -5547000000 | JPY |
| Purchase of property inv cf IFRS | CurrentYearDuration | -6618000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YearDuration | 13237000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYearDuration | 658000000 | JPY |
| Proceeds from sale of investment property inv cf IFRS | Prior1YearDuration | － | JPY |
| Proceeds from sale of investment property inv cf IFRS | CurrentYearDuration | 3400000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YearDuration | -40000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYearDuration | -122000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YearDuration | -2806000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYearDuration | -616000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | Prior1YearDuration | 89000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | CurrentYearDuration | － | JPY |
| Payments for sale of subsidiaries inv cf IFRS | Prior1YearDuration | － | JPY |
| Payments for sale of subsidiaries inv cf IFRS | CurrentYearDuration | -18000000 | JPY |
| Payments for leasehold deposits and guarantee deposits inv cf IFRS | Prior1YearDuration | -536000000 | JPY |
| Payments for leasehold deposits and guarantee deposits inv cf IFRS | CurrentYearDuration | -230000000 | JPY |
| Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRS | Prior1YearDuration | 35000000 | JPY |
| Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRS | CurrentYearDuration | 29000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YearDuration | -9000000 | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYearDuration | -3000000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YearDuration | 28000000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYearDuration | 4000000 | JPY |
| Proceeds from the release of escrowed funds inv cf IFRS | Prior1YearDuration | 108000000 | JPY |
| Proceeds from the release of escrowed funds inv cf IFRS | CurrentYearDuration | － | JPY |
| Income from investment refunds IFRS | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |